Synapse

← Safety and Risk of Pharmacotherapy

Papers in Safety and Risk of Pharmacotherapy

Page 1 · newest first

  1. Drug-Induced Kidney Injury: Triggers and Outpatient Management Strategies (Review)Safety and Risk of Pharmacotherapy · 2026
  2. Valsartan+Sacubitril Efficacy and Safety in Hypertensive Disease in Adults: A Prospective Randomised Control TrialSafety and Risk of Pharmacotherapy · 2025
  3. Fatal Rhabdomyolysis after Rosuvastatin Dose Modification in Acute Coronary Syndrome: A Case ReportSafety and Risk of Pharmacotherapy · 2025
  4. Preclinical Studies of Modern Radiopharmaceuticals: Expert Approaches to Evaluating the ResultsSafety and Risk of Pharmacotherapy · 2025
  5. Therapeutic Potential of Myo-Inositol in Male Infertility: Correction of Spermatogenesis Parameters and Oxidative Stress (Review)Safety and Risk of Pharmacotherapy · 2025
  6. Safety of Post-Infarction Dual Antiplatelet Therapy and Patient Adherence: EMIAS Data AnalysisSafety and Risk of Pharmacotherapy · 2025
  7. The Safety of the Use of Antidepressants: Analysis of the Russian Database of Spontaneous ReportsSafety and Risk of Pharmacotherapy · 2025
  8. Pharmacogenetic Biomarkers of Clozapine-Induced Sialorrhoea: A Systematic ReviewSafety and Risk of Pharmacotherapy · 2025
  9. Pharmacovigilance and Ranitidine Withdrawal Awareness among Libyan Private Pharmacies (Gharyan): A Cross-Sectional StudySafety and Risk of Pharmacotherapy · 2025
  10. Ketoprofen Comparative Pharmacokinetics Analysis in Humans and Animals: A ReviewSafety and Risk of Pharmacotherapy · 2025
  11. Multi-Omics in Predicting Lamotrigine Neurotoxicity: Current Opportunities (Review)Safety and Risk of Pharmacotherapy · 2025
  12. Pharmacovigilance in Medical Organisations: Regional Reporting Experience on Adverse Drug Reactions and New Roszdravnadzor RequirementsSafety and Risk of Pharmacotherapy · 2025
  13. Pharmacogenetic Testing as a Tool to Prevent Isoniazid-Induced Hepatotoxicity in Pulmonary Tuberculosis Therapy: A Case ReportSafety and Risk of Pharmacotherapy · 2025
  14. Risk Assessment Algorithms in Pharmacovigilance: A ReviewSafety and Risk of Pharmacotherapy · 2025
  15. Local Administration of pCMV-VEGF165 Plasmid Encoding VEGF Stimulates Tissue Regeneration after Cold Injury in RatsSafety and Risk of Pharmacotherapy · 2025
  16. Pharmacovigilance in the Geriatric Population: Analysis of Risk Management Plans for Medicinal Products in Russia in 2024Safety and Risk of Pharmacotherapy · 2025
  17. Thrombocytopenia as a Side Effect of Heparin Therapy and COVID-19 Vaccination: A ReviewSafety and Risk of Pharmacotherapy · 2025
  18. Predicting the Relative Risk of Pharmacotherapy Based on a Mathematical Model of Age-Related Decline in Homeostasis in Elderly and Senile PatientsSafety and Risk of Pharmacotherapy · 2025
  19. Implementation of the 3Rs Concept in Quality Control of Biologicals: Status and Prospects (Review)Safety and Risk of Pharmacotherapy · 2025
  20. Circulating MicroRNAs Are Promising Biomarkers for Assessing the Risk of Antipsychotic-Induced Metabolic Syndrome (Review): Part 2Safety and Risk of Pharmacotherapy · 2025
  21. Drug Allergy in Adults at a Multidisciplinary Hospital: Prevalence Assessment Using the Global Trigger ToolSafety and Risk of Pharmacotherapy · 2025
  22. Circulating MicroRNAs Are Promising Biomarkers for Assessing the Risk of Antipsychotic-Induced Metabolic Syndrome (Review): Part 1Safety and Risk of Pharmacotherapy · 2025
  23. Cardiovascular Safety Assessment of Medicines in Preclinical In vivo Studies: A ReviewSafety and Risk of Pharmacotherapy · 2025
  24. Effects of Food on the Bioavailability of Medicinal Products in Bioequivalence Studies: A Comparative Analysis of Regulatory DocumentsSafety and Risk of Pharmacotherapy · 2025
  25. Improving the Pharmacovigilance System in Medical Organisations as an Opportunity to Enhance the Quality of PharmacotherapySafety and Risk of Pharmacotherapy · 2025
  26. Anti-amyloid Monoclonal Antibodies for Alzheimer’s Disease: A New Hope? (Review)Safety and Risk of Pharmacotherapy · 2025
  27. Safety Profile Evaluation of an Original Mesenchymal Stromal Cell Secretome-Based Medicinal Product after Intratesticular Injection in RabbitsSafety and Risk of Pharmacotherapy · 2025
  28. The Effect of Potentially Hepatotoxic Medicinal Products on Alanine Transaminase Levels in COVID-19 Patients: A Case–Control StudySafety and Risk of Pharmacotherapy · 2025
  29. Relevant Species Selection for Preclinical Safety Studies of Medicines: A ReviewSafety and Risk of Pharmacotherapy · 2025
  30. WoE Analysis and Key Risk Factors in Preclinical Development of Medicinal Products: A ReviewSafety and Risk of Pharmacotherapy · 2024
  31. Adverse Reactions to Intravenous Immunoglobulin Therapy: An Analysis of the Russian National Pharmacovigilance DatabaseSafety and Risk of Pharmacotherapy · 2024
  32. Current Mesalazine Products: Differences in Enteric-Coated Dosage Forms and Pharmaceutical Risks of Clinical Efficacy Reduction (Review)Safety and Risk of Pharmacotherapy · 2024
  33. Medication Errors Associated with the Use of Levofloxacin: An Analysis of the National Database of Spontaneous ReportsSafety and Risk of Pharmacotherapy · 2024
  34. Social Media as a Source of Information for the Detection of Adverse Drug Reactions in Post-Marketing Surveillance: A ReviewSafety and Risk of Pharmacotherapy · 2024
  35. Neurotropic Effect of Botulinum Toxin and the Potential of Specific Serum Therapy in Botulism (Review)Safety and Risk of Pharmacotherapy · 2024
  36. Off-Label Use of Neovasculgen for II–III Degree Foot Frostbite: A Case ReportSafety and Risk of Pharmacotherapy · 2024
  37. Antipsychotic-Induced Parkinsonism: A Risk Assessment Scale and Personalised Diagnosis AlgorithmSafety and Risk of Pharmacotherapy · 2024
  38. Postmarketing Surveillance: Review of Open Sources of Drug Safety DataSafety and Risk of Pharmacotherapy · 2024
  39. Aggressive Pharmacotherapy in Reproductive Medicine. Pregnancy and Medicines (Author’s Perspective)Safety and Risk of Pharmacotherapy · 2024
  40. Genetic features of a patient may influence the efficacy and safety profile of a medicinal productSafety and Risk of Pharmacotherapy · 2024
  41. Risk Management Plan: Expert Review of Applications for Marketing Authorisation in the EAEU Depending on the Type of Medicinal Product (Review)Safety and Risk of Pharmacotherapy · 2024
  42. Determination of Elemental Impurities in Gelatine Capsules by Inductively Coupled Plasma Mass SpectrometrySafety and Risk of Pharmacotherapy · 2024
  43. Combined Oral Contraceptives for Polycystic Ovary Syndrome: Pro and Contra (Review)Safety and Risk of Pharmacotherapy · 2024
  44. Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)Safety and Risk of Pharmacotherapy · 2024
  45. Preclinical Safety Assessment of Antineoplastic Agents Based on Live Non-Pathogenic EnterovirusesSafety and Risk of Pharmacotherapy · 2024
  46. Potentially Inappropriate Medications for Use in Older Adults: Beers Criteria (2023 American Geriatrics Society Guidelines)Safety and Risk of Pharmacotherapy · 2024
  47. Antipsychotic-Induced QT Prolongation and Torsade de Pointes in Patients with Mental Disorders: A ReviewSafety and Risk of Pharmacotherapy · 2024
  48. Analysis of the Consumption of Medicinal Products Associated with a High Risk of Drug-Induced Liver Injury in Patients with COVID-19Safety and Risk of Pharmacotherapy · 2024
  49. Pharmacogenomic Predictors of Antibiotic-Associated Drug-Induced Liver Injury in Critically Ill Children: Observational Study ResultsSafety and Risk of Pharmacotherapy · 2024
  50. Enhancing the Efficacy and Safety of Methotrexate Treatment: A Focus on Drug Interactions (Review)Safety and Risk of Pharmacotherapy · 2024